TABLE 3.
Characteristic | No. | % |
---|---|---|
Sex (n = 283) | ||
Male | 115 | 40 |
Female | 168 | 57 |
Location of exposure | ||
Residence | 217 | 75 |
Commercial location | 14 | 5 |
Other | 16 | 6 |
Not disclosed | 42 | 14 |
Exposure route | ||
Inhalation/nasal | 273 | 95 |
Ingestion | 9 | 3 |
Both | 7 | 2 |
Health effect | ||
Headache | 175 | 61 |
Nausea | 94 | 33 |
Dizziness | 84 | 29 |
Vomiting | 56 | 19 |
Syncope or loss of consciousness | 39 | 13 |
Lethargy or drowsiness | 34 | 12 |
Tachycardia | 17 | 6 |
Dyspnea | 11 | 4 |
Confusion | 9 | 3 |
Muscle weakness | 9 | 3 |
Chest pain | 8 | 3 |
Respiratory arrest | 8 | 3 |
Other | 134 | 46 |
Treatment location | ||
Emergency department | 176 | 61 |
Admitted to hospital | 53 | 18 |
No healthcare treatment | 32 | 11 |
Unknown | 28 | 10 |
Therapy performed | ||
Oxygen | 204 | 71 |
Fresh air | 99 | 34 |
Hyperbaric oxygen | 36 | 12 |
Antiemetics | 9 | 3 |
Fluids | 8 | 3 |
IV | 4 | 1 |
Other | 27 | 9 |
Clinical outcome | ||
Minor | 164 | 57 |
Moderate | 95 | 33 |
Major | 25 | 9 |
Death | 4 | 1 |
n =289. The 5 states were New York, New Jersey, Pennsylvania, Connecticut, and West Virginia.